INTRODUCTION {#s1}
============

Brain tumors are the most common pediatric solid tumors and the leading cause of cancer mortality in children. High-dose ionizing radiation and rare inherited syndromes are the only established risk factors for brain tumors, causing a small proportion of cases \[[@R1]\]. Thus, brain tumors are considered as multifactorial disorders resulting from progressive accumulation of genetic and epigenetic alterations in concert with environmental exposures. It has been suggested that genetic polymorphisms in four main pathways including DNA repair, cell cycle, metabolism, and inflammation play an important role in brain carcinogenesis \[[@R2]\]. Therefore, candidate gene-association studies of adult brain tumors have mainly focused on these four hypothesized pathways to identify genetic susceptibility factors for adult brain tumors \[[@R3]--[@R9]\].

Whereas a considerable number of candidate gene-association studies are available on adult brain tumors, very few and small genetic studies have been performed on brain tumors in children and adolescents \[[@R10]--[@R13]\], due to difficulties in collecting a sufficient number of DNA samples. Hence, the role of genetic polymorphisms in pediatric brain tumor (PBT) etiology is largely unknown. However, some studies have found similar genetic mutation patterns for adult and pediatric brain tumor progression within specific histological types \[[@R14]--[@R18]\]. These similarities in prognostic factors provide an important starting point for identifying candidate genetic risk factors for PBTs; that might be similar to those involved in adult brain tumorigenesis \[[@R19]\]. Moreover, in our previous genetic association study of PBT risk, we concluded that single nucleotide polymorphisms (SNPs) identified by genome-wide association studies (GWAS) on adult glioma might also be associated with the risk of brain tumors in children \[[@R20]\].

The aim of this study, which represents the largest series of PBT cases to date, was to determine whether the SNPs identified by candidate gene-association studies on adult brain tumors, involved in the four main pathways discussed above, are also related to pediatric brain tumor risk.

RESULTS {#s2}
=======

We successfully genotyped 63 SNPs in 245 cases and 489 controls. The distributions of allele frequencies in 3 SNPs (rs4444903, rs9288516, and rs61754966) were not in agreement with HWE (*p* \< 0.001) and therefore these SNPs were dropped from analyses. As shown in Table [1](#T1){ref-type="table"}, the age and sex distributions were similar in cases and controls.

###### Characteristics of cases and controls

  Characteristics                                                            Cases       Astrocytomas   Non-astrocytomas   Controls
  -------------------------------------------------------------------------- ----------- -------------- ------------------ -----------
  **No. of participants**                                                    245         134            111                489
  **Sex**                                                                                                                  
  Males                                                                      136 (56%)   74 (55%)       62 (56%)           261 (53%)
  Females                                                                    109 (44%)   60 (45%)       49 (44%)           228 (47%)
  **Age-group (at diagnosis/reference date)**                                                                              
  7--9 years old                                                             48 (20%)    28 (21%)       20 (18%)           112 (23%)
  10--14 years old                                                           108 (44%)   60 (45%)       48 (43%)           219 (45%)
  15--19 years old                                                           89 (36%)    46 (34%)       43 (39%)           158 (32%)
  **Country**                                                                                                              
  Sweden                                                                     106 (43%)   48 (36%)       58 (52%)           174 (36%)
  Norway                                                                     24 (10%)    15 (11%)       9 (8%)             62 (13%)
  Denmark                                                                    62 (25%)    37 (28%)       25 (23%)           134 (27%)
  Switzerland                                                                53 (22%)    34 (25%)       19 (17%)           119(24%)
  **Type of tumor (ICCC-3 group III)**[^a^](#tfn_001){ref-type="table-fn"}                                                 
  Astrocytoma (IIIb)                                                         134 (55%)                                     
  Pilocytic astrocytoma                                                      93                                            
  Supependymal giant cell astrocytoma                                        5                                             
  Pleomorphic xanthoastrocytoma                                              4                                             
  Diffuse astrocytoma                                                        13                                            
  Anaplastic astrocytoma                                                     11                                            
  Fibrillary astrocytoma                                                     2                                             
  Glioblastoma                                                               5                                             
  Giant cell glioblastoma                                                    1                                             
  Other gliomas (IIId)                                                       20 (8%)                                       
  Malignant glioma                                                           11                                            
  Oligoastrocytoma                                                           2                                             
  Oligodendroglioma                                                          6                                             
  Anaplastic oligodendroglioma                                               1                                             
  Ependymoma (IIIa)                                                          19 (8%)                                       
  Subependymoma                                                              2                                             
  Choroid plexus papilloma                                                   4                                             
  Choroid plexus caricinoma                                                  1                                             
  Ependymoma                                                                 7                                             
  Papillary ependymoma                                                       1                                             
  Anaplastic ependymoma                                                      4                                             
  Intracranial embryonal tumors (IIIc)                                       7 (3%)                                        
  CNS primitive neuroectodermal tumor                                        6                                             
  Neuroepithelioma                                                           1                                             
  Other specified intracranial neoplasms (IIIe)                              49 (20%)                                      
  Germinoma                                                                  7                                             
  Yolk sac tumor                                                             1                                             
  Teratoma, mature                                                           1                                             
  Haemangioblastoma                                                          1                                             
  Desmoplastic infantile ganglioglioma                                       2                                             
  Dysembryoplastic neuroepithelial tumor                                     6                                             
  Ganglioglioma                                                              26                                            
  Anaplastic ganglioglioma                                                   1                                             
  Centrol neurocytoma                                                        3                                             
  Neurilemoma                                                                1                                             
  Unspecified intracranial neoplasm (IIIf)                                   16 (6%)                                       

Restricted to ICD-O-3 location C71, subclassified according to WHO histological subclassification, 2007; patients with neurofibromatosis and tuberous sclerosis were excluded.

As Table [2](#T2){ref-type="table"} illustrates, the A alleles of *EGFR* rs730437 (OR~DOM~ 0.59 \[95% CI 0.42-0.83\], *p* = 0.002) and *EGFR* rs11506105 (OR~DOM~ 0.71 \[95% CI 0.51--0.98\], *p* = 0.036) involved in cell cycle pathway were associated with decreased susceptibility to PBTs, whereas the A allele of *ERCC1* rs3212986 (OR~DOM~ 1.53 \[95% CI 1.11--2.09\], *p* = 0.009) involved in DNA repair pathway was associated with an increased risk of these tumors. Moreover, the interactions between these SNPs and covariates including age, sex and country were not significant.

###### Summary results for SNPs associated with pediatric brain tumors

  SNP          Chr.   Gene      Pathway      Location (bp)   Minor allele   MAF[^a^](#tfn_002){ref-type="table-fn"} in cases   MAF[^a^](#tfn_002){ref-type="table-fn"} in controls   Model       OR[^b^](#tfn_003){ref-type="table-fn"}   95% CI       *P*     CHISQ   Pinter[^c^](#tfn_004){ref-type="table-fn"}
  ------------ ------ --------- ------------ --------------- -------------- -------------------------------------------------- ----------------------------------------------------- ----------- ---------------------------------------- ------------ ------- ------- --------------------------------------------
  rs730437     7      *EGFR*    Cell cycle   55215018        A              0.44                                               0.51                                                  Dominant    0.59                                     0.42--0.83   0.002           0.435
                                                                                                                                                                                     Recessive   0.79                                     0.56--1.15   0.23            
                                                                                                                                                                                     Additive    0.75                                     0.60--0.93   0.009           
                                                                                                                                                                                     Allelic                                                           0.016   5.77    
  rs11506105   7      *EGFR*    Cell cycle   55220177        A              0.39                                               0.45                                                  Dominant    0.71                                     0.51--0.98   0.036           0.285
                                                                                                                                                                                     Recessive   0.87                                     0.59--1.28   0.477           
                                                                                                                                                                                     Additive    0.82                                     0.66--1.02   0.079           
                                                                                                                                                                                     Allelic                                                           0.099   2.73    
  rs3212986    19     *ERCC1*   DNA Repair   45912736        A              0.27                                               0.21                                                  Dominant    1.53                                     1.11--2.09   0.009           0.311
                                                                                                                                                                                     Recessive   1.14                                     0.59--2.19   0.699           
                                                                                                                                                                                     Additive    1.34                                     1.04--1.73   0.023           
                                                                                                                                                                                     Allelic                                                           0.029   4.78    

MAF=Minor Allele Frequency

OR adjusted for age, sex, and country

*P* value for interactions between SNPs and demographic variables including age, sex and country.

The stratified analyses of two histological subtypes indicated that the protective effect of *EGFR* rs730437 remained significant in both patients with astrocytoma and non-astrocytoma tumor subtypes (p~DOM~=0.018 and p~DOM~=0.014, respectively), whereas the risk effect of *ERCC1* rs3212986 was more evident in patients with astrocytoma subtype (p~DOM~=0.002). Moreover, a decreased risk of astrocytoma subtype associated with the C alleles of *CHAF1A* rs243341 and rs2992 as well as the T allele of *XRCC1* rs25487 involved in DNA repair pathway was detected (p~DOM~=0.040, p~DOM~=0.049, and p~DOM~=0.033, respectively). In addition, the stratified analyses showed an increased risk of non-astrocytoma tumor subtype associated with the C alleles of *EGFR* rs9642393, *EME1* rs12450550, and *ATM* rs170548, and the T allele of *GLTSCR1* rs1035938 (p~REC~=0.021, p~REC~=0.001, p~DOM~=0.041, and p~REC~=0.027, respectively) as well as a decreased risk of this subtype associated with the A allele of *XRCC4* rs7721416 and the C allele of *XRCC4* rs2662242 (DNA repair pathway) (p~REC~=0.032 and p~REC~=0.024, respectively) (Tables [3](#T3){ref-type="table"} and [4](#T4){ref-type="table"}).

###### Summary results for SNPs associated with astrocytoma subtype

  SNP         Chr.   Gene       Pathway      Location (bp)   Minor allele   MAF[^a^](#tfn_005){ref-type="table-fn"} in cases   MAF[^a^](#tfn_005){ref-type="table-fn"} in controls   Model       OR[^b^](#tfn_006){ref-type="table-fn"}   95% CI       *P*     CHISQ
  ----------- ------ ---------- ------------ --------------- -------------- -------------------------------------------------- ----------------------------------------------------- ----------- ---------------------------------------- ------------ ------- -------
  rs730437    7      *EGFR*     Cell cycle   55215018        A              0.44                                               0.51                                                  Dominant    0.60                                     0.39--0.91   0.018   
                                                                                                                                                                                     Recessive   0.84                                     0.54--1.33   0.462   
                                                                                                                                                                                     Additive    0.77                                     0.59--1.01   0.058   
                                                                                                                                                                                     Allelic                                                           0.064   3.42
  rs3212986   19     *ERCC1*    DNA Repair   45912736        A              0.29                                               0.21                                                  Dominant    1.87                                     1.26--2.76   0.002   
                                                                                                                                                                                     Recessive   0.95                                     0.40--2.25   0.914   
                                                                                                                                                                                     Additive    1.49                                     1.09--2.04   0.011   
                                                                                                                                                                                     Allelic                                                           0.012   6.36
  rs243341    19     *CHAF1A*   DNA Repair   4405106         C              0.23                                               0.29                                                  Dominant    0.66                                     0.45--0.98   0.040   
                                                                                                                                                                                     Recessive   0.62                                     0.28--1.35   0.228   
                                                                                                                                                                                     Additive    0.71                                     0.52--0.98   0.036   
                                                                                                                                                                                     Allelic                                                           0.033   4.57
  rs2992      19     *CHAF1A*   DNA Repair   4443046         C              0.23                                               0.29                                                  Dominant    0.67                                     0.45--0.99   0.049   
                                                                                                                                                                                     Recessive   0.64                                     0.29--1.39   0.262   
                                                                                                                                                                                     Additive    0.72                                     0.53--0.99   0.046   
                                                                                                                                                                                     Allelic                                                           0.042   4.13
  rs25487     19     *XRCC1*    DNA Repair   44055726        T              0.30                                               0.36                                                  Dominant    0.66                                     0.44--0.97   0.033   
                                                                                                                                                                                     Recessive   0.87                                     0.48--1.59   0.652   
                                                                                                                                                                                     Additive    0.77                                     0.57--1.03   0.076   
                                                                                                                                                                                     Allelic                                                           0.077   3.13

MAF=Minor Allele Frequency

OR adjusted for age, sex, and country.

###### Summary results for SNPs associated with non-astrocytoma subtype

  SNP          Chr.   Gene        Pathway      Location (bp)   Minor allele   MAF[^a^](#tfn_007){ref-type="table-fn"} in cases   MAF[^a^](#tfn_007){ref-type="table-fn"} in controls   Model       OR[^b^](#tfn_008){ref-type="table-fn"}   95% CI       *P*     CHISQ
  ------------ ------ ----------- ------------ --------------- -------------- -------------------------------------------------- ----------------------------------------------------- ----------- ---------------------------------------- ------------ ------- -------
  rs730437     7      *EGFR*      Cell cycle   55215018        A              0.44                                               0.51                                                  Dominant    0.56                                     0.36--0.89   0.014   
                                                                                                                                                                                       Recessive   0.75                                     0.46--1.25   0.271   
                                                                                                                                                                                       Additive    0.72                                     0.53--0.97   0.030   
                                                                                                                                                                                       Allelic                                                           0.060   3.54
  rs9642393    7      *EGFR*      Cell cycle   55245647        C              0.3                                                0.26                                                  Dominant    1.07                                     0.70--1.63   0.754   
                                                                                                                                                                                       Recessive   2.21                                     1.13--4.35   0.021   
                                                                                                                                                                                       Additive    1.23                                     0.89--1.69   0.214   
                                                                                                                                                                                       Allelic                                                           0.227   1.46
  rs12450550   17     *EME1*      DNA Repair   48456193        C              0.38                                               0.28                                                  Dominant    1.28                                     0.84--1.95   0.257   
                                                                                                                                                                                       Recessive   2.48                                     1.42--4.33   0.001   
                                                                                                                                                                                       Additive    1.42                                     1.06--1.91   0.019   
                                                                                                                                                                                       Allelic                                                           0.004   8.39
  rs170548     11     *ATM*       DNA Repair   108234836       C              0.36                                               0.31                                                  Dominant    1.57                                     1.02--2.42   0.041   
                                                                                                                                                                                       Recessive   0.98                                     0.49--1.92   0.947   
                                                                                                                                                                                       Additive    1.27                                     0.93--1.72   0.135   
                                                                                                                                                                                       Allelic                                                           0.096   2.78
  rs1035938    19     *GLTSCR1*   DNA Repair   48183771        T              0.29                                               0.24                                                  Dominant    1.15                                     0.75--1.76   0.513   
                                                                                                                                                                                       Recessive   2.14                                     1.09--4.19   0.027   
                                                                                                                                                                                       Additive    1.27                                     0.92--1.74   0.145   
                                                                                                                                                                                       Allelic                                                           0.085   2.96
  rs7721416    5      *XRCC4*     DNA Repair   82434993        A              0.41                                               0.47                                                  Dominant    0.85                                     0.54--1.35   0.494   
                                                                                                                                                                                       Recessive   0.51                                     0.27--0.94   0.032   
                                                                                                                                                                                       Additive    0.76                                     0.56--1.04   0.089   
                                                                                                                                                                                       Allelic                                                           0.083   2.99
  rs2662242    5      *XRCC4*     DNA Repair   82484885        C              0.42                                               0.48                                                  Dominant    0.92                                     0.57--1.47   0.720   
                                                                                                                                                                                       Recessive   0.49                                     0.26--0.91   0.024   
                                                                                                                                                                                       Additive    0.78                                     0.57--1.06   0.114   
                                                                                                                                                                                       Allelic                                                           0.104   2.65

MAF=Minor Allele Frequency

OR adjusted for age, sex, and country.

Non-significant findings as well as the significant findings with wide confidence intervals are shown in the online appendix [Tables S1](#SD2){ref-type="supplementary-material"}--[S3](#SD4){ref-type="supplementary-material"}.

Strong LD (D\' ≥ 0.95) was observed between four genotyped SNPs in *EGFR* (rs730437, rs11506105, rs4947986, and rs3752651) in which five haplotypes with frequency of \> 1% were detected. In the *EGFR* block, the distribution of haplotypes was suggestively different between PBT patients and controls (χ^2^ = 8.1, df = 4, *p* = 0.089) and the most common haplotype (CGGT) had a significant risk effect compared with the other haplotypes combined (OR 1.31 \[95% CI 1.05--1.64\], *p* = 0.017) (Table [5](#T5){ref-type="table"}). In the astrocytoma subgroup, the *CHAF1A* block (rs243341, rs105038, rs243356, and rs2992) with three haplotypes with frequency of \>1% was found; however, the distribution of haplotypes in this haploblock was not significantly different between patients and controls (χ^2^ = 2.95, df = 2, *p* = 0.229). Moreover, in the non-astrocytoma subgroup, two haploblocks including *ATM* (rs228599, rs664143, rs170548, rs3092993, and rs3092992) and *XRCC4* (rs7721416 and rs2662242) with, respectively, five and three haplotypes with frequency of \> 1% were observed; nevertheless, in none of these haploblocks, the distribution of haplotypes was significantly different between patients and controls (χ^2^ = 1.92, df = 4, *p* = 0.751 and χ^2^ = 2.98, df = 2, *p* = 0.226, respectively).

###### Haplotype analysis of SNPs in *EGFR*

  SNPs                                               Haplotype   Frequency   OR[^a^](#tfn_009){ref-type="table-fn"}   95% CI       *P*
  -------------------------------------------------- ----------- ----------- ---------------------------------------- ------------ -------
  EGFR: rs730437, rs11506105, rs4947986, rs3752651   AAAC        0.21        0.92                                     0.69--1.23   0.569
                                                     AAAT        0.08        0.70                                     0.44--1.11   0.126
                                                     AAGT        0.14        0.82                                     0.59--1.15   0.247
                                                     AGGT        0.06        0.69                                     0.41--1.15   0.153
                                                     CGGT        0.51        1.31                                     1.05--1.64   0.017

Odds ratio for haplotype compared with all other haplotypes adjusted for age, sex, and country.

As described above, 248 testing procedures were performed. When the Bonferroni correction is applied, the reference *p* value is 0.0002 for an experiment-wide significance level of 0.05, and 0.0004 for a significance level of 0.10; none of the reported associations met these limits. As summarized in [Table S4](#SD1){ref-type="supplementary-material"}, no significant SNP-SNP interactions were observed (*p* \< 0.001).

DISCUSSION {#s3}
==========

This study suggests that SNPs involved in cell cycle and DNA repair pathways previously linked with brain tumors in adults are also associated with pediatric brain tumorigenesis. The results indicate that the A alleles of *EGFR* rs730437 and rs11506105 may decrease susceptibility to PBTs, whereas the A allele of *ERCC1* rs3212986 may increase the risk of these tumors. Moreover, the C alleles of *CHAF1A* rs243341 and rs2992 as well as the T allele of *XRCC1* rs25487 were associated with a decreased risk of astrocytoma subtype. In addition, an increased risk of non-astrocytoma tumor subtype associated with the C alleles of *EGFR* rs9642393, *EME1* rs12450550, and *ATM* rs170548, and the T allele of *GLTSCR1* rs1035938 as well as a decreased risk of this subtype associated with the A allele of *XRCC4* rs7721416 and the C allele of *XRCC4* rs2662242 were detected.

Genetic and epigenetic aberrations involved in cell cycle and DNA repair pathways have been proposed to play a role in PBT pathogenesis and progression \[[@R21]--[@R25]\]. Overexpression of the epidermal growth factor receptor (EGFR), which plays an important role in cell growth and development through the cell cycle pathway, is shown to be common and correlated with tumor grade in pediatric brain tumors \[[@R26], [@R27]\]. The function of genetic variants of *EGFR* is still unclear; however, intronic variations of *EGFR* found in this study may affect EGFR expression and play a role in pediatric brain tumorigenesis.

DNA repair is an important mechanism to maintain genomic stability and its functional failure may lead to carcinogenesis. Somatic variations of DNA repair genes have been identified in PBTs \[[@R28]--[@R30]\]; however, no study has investigated the role of DNA repair gene variations in PBT etiology. In this study, we examined the association between PBT risk and 37 SNPs in 17 DNA repair genes, shown to be associated with risk of adult brain tumors. Of these, 9 SNPs in 7 DNA repair genes (*ERCC1*, *CHAF1A*, *XRCC1*, *EME1*, *ATM*, *GLTSCR1*, and *XRCC4*) were also associated with susceptibility to PBTs. A few studies have previously indicated that DNA repair gene alterations may increase the predisposition to cancer formation in children \[[@R31], [@R32]\]. Moreover, these variations might predict the tumor drug sensitivity and the treatment outcome \[[@R33]\].

The *ERCC1* gene encodes excision repair cross-complementing group 1 which is involved in DNA nucleotide excision repair (NER) pathway \[[@R34]\]. The result of association between the A allele of *ERCC1* rs3212986 and increased risk of PBTs is in line with our finding in a meta-analysis of this polymorphism in adult brain tumors \[[@R3]\]. *XRCC1* which encodes an enzyme named X-ray cross-complementing group 1, plays an important role in base excision repair pathway (BER) \[[@R35]\]. Chromatin assembly factor 1, subunit A (CHAF1A) is involved in DNA mismatch repair (MMR) during the correction of DNA replication errors \[[@R36]\]. *XRCC4* encodes X-ray repair complementing defective repair in Chinese hamster cells 4 that functions in the repair of DNA double-strand breaks (DSBs) produced by ionizing radiation and restriction enzymes \[[@R37]\].

*EME1* encodes essential meiotic structure-specific endonuclease 1 which forms an endonuclease complex with methyl methanesulfonate-sensitive UV-sensitive 81 protein (MUS81) and plays an important role in DNA repair and maintaining of genome integrity \[[@R38]\]. *ATM* encodes a protein kinase which is a member of phosphatidyl inositol 3-kinase-like kinase (PIKK) family. ATM is a key regulator of cell cycle checkpoint signaling pathways which responds to DNA strand breaks by inducing cell-cycle arrest and hence facilitates DNA repair \[[@R39]\]. *GLTSCR1* stands for glioma tumor suppressor candidate region 1 and *GLTSCR1* rs1035938 polymorphism alters a CpG site within the 5′ CpG island of the gene. This germ-line alteration might affect the transcription of *GLTSCR1* and other candi-date genes in the region \[[@R40]\].

The present study was conducted based on the largest series of pediatric brain tumor cases to date with the purpose to investigate the association between genetic polymorphisms along with four main pathways hypothesized to be involved in brain tumorigenesis and PBT risk. Although investigating the effect of environmental risk factors was not the aim of our study, the fact that we did not take into consideration the possible gene-environment interactions is a limitation of this work. Moreover, due to shortage of large enough pediatric patient materials with access to DNA samples, we were not able to replicate our findings. Therefore, additional studies are necessary to validate these results, explore the mechanisms through which these genetic polymorphisms influence cancer susceptibility, and to investigate gene-environment interactions underling risk of PBTs.

Since this study describes the association between genetic variations and risk of pediatric brain tumors, it provides an important starting point for understanding the mechanisms behind the PBT etiology that in turn might lead to identifying clinically meaningful genetic risk and protective factors and eventually cancer prevention and treatment.

In conclusion, the present study indicates that while the minor alleles of polymorphisms in *ERCC1* may increase the risk of PBTs, the minor alleles of SNPs in *EGFR* are associated with decreased susceptibility to these tumors. Furthermore, polymorphisms in *CHAF1A* and *XRCC1* are associated with the risk of astrocytoma, whereas SNPs in *EME1*, *ATM*, *GLTSCR1*, and *XRCC4* are associated with susceptibility to non-astrocytoma subtypes. Therefore, genetic polymorphisms in cell cycle and DNA repair pathways associated with susceptibility to adult brain tumors seem also to be associated with PBT risk suggesting that pediatric and adult brain tumors might share similar etiological pathways.

MATERIALS AND METHODS {#s4}
=====================

Study subjects and procedures {#s4_1}
-----------------------------

This population-based case-control study is based on the Cefalo study, a large international study of brain tumors in children and adolescents conducted in Sweden, Denmark, Norway, and Switzerland. Details of the study methods have been described previously \[[@R41]\]. Briefly, all children aged 7--19 years during the period between 1 April 2004 and 31 August 2008, diagnosed with a primary intracranial brain tumor defined according to the International Classification of Childhood Cancer, third edition (ICCC-3), group III \[[@R42]\], restricted to ICD-O-3 location C71, were considered as case subjects. Cases were subclassified according to the fourth edition of the World Health Organization (WHO) classification of tumors of the central nervous system \[[@R43]\]. Participants with neurofibromatosis or tuberous sclerosis were excluded from analyses. Medulloblastoma cases were excluded here since they will be included in a separate study. Controls were randomly selected from the population registers and matched to the cases by age, sex, and geographic region. A total of 352 (82%) cases and 646 (71%) controls participated in the interviews. The study was approved by the National data protection boards and ethical committees in all participating countries, and written informed consent was obtained from all participants and/or their parents.

Saliva collection and DNA extraction were performed using the Oragene self-collection kit (DNA Genotek, Ottawa, ON, Canada) and the DNA yield was quantitated using PicoGreen (Invitrogen, Carlsbad, CA, USA), according to the standard protocols. This study, in total, included saliva DNA of 245 cases and 489 controls. Distribution of diagnostic subtypes among cases were 134 astrocytoma, 19 ependymoma, 7 intracranial embryonal tumors, 20 other gliomas, 49 other specified intracranial neoplasms, and 16 with unspecified intracranial neoplasms (Table [1](#T1){ref-type="table"}).

Selection of candidate SNPs and genotyping {#s4_2}
------------------------------------------

The PubMed database was searched (up to December 2012) using combinations of the following terms: 'brain tumor', 'single nucleotide polymorphism', 'association', 'gene', 'risk', 'case control', 'susceptibility', and 'polymorphism' to identify all the published peer-reviewed candidate gene-association studies of brain tumors. All the statistically significant SNPs reported by childhood brain tumor genetic association studies \[[@R11]--[@R13]\] as well as the SNPs reported by at least two candidate gene-association studies as being statistically associated with the risk of adult brain tumors \[[@R3]--[@R9], [@R44]--[@R49]\] were selected for genotyping.

Of 68 selected SNPs, 63 SNPs were satisfactorily genotyped (success rate ≥ 80%). Genotyping was performed at the Mutation Analysis core Facility (MAF), Clinical Research Centre, Huddinge University Hospital, Stockholm, Sweden, with staff blinded to sample status, using the Sequenom iPlex Gold platform with matrix-assisted laser desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry. The average success rate was 97% and the concordance rate for duplicate genotyping was 100%.

Statistical analyses {#s4_3}
--------------------

The χ^2^ goodness-of-fit test was used to examine the consistency of allele frequencies with Hardy-Weinberg equilibrium (HWE) among the controls and *p* \< 0.001 was considered statistically significant. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated using unconditional logistic regression modelling to evaluate the association between each SNP and the risk of PBT based on the Cochran--Armitage trend test of additivity (trend) as well as dominant (DOM) and recessive (REC) models, with adjustment for age, sex, and country. We applied the χ^2^ test to compare the allelic frequencies of the genotyped SNPs between cases and controls as well as the Wald test to evaluate the significance of interactions between SNPs and demographic variables including age, sex and country. SNP-SNP interactions were investigated for pairwise combinations of all the SNPs involved in the same pathway and *p* \< 0.001 was set as the significance level of interaction analyses. Stratified analyses were performed by astrocytoma alone and the other tumor types combined (including ependymoma, intracranial embryonal tumors (except medulloblastoma), other gliomas, other specified intracranial neoplasms, and unspecified intracranial neoplasm); in order to increase the statistical power. To measure the linkage disequilibrium (LD) between the genotyped SNPs, D\' was calculated. Haploblocks were defined based on the default LD block parameters in Haploview v4.2. Haplotype analyses were performed for the haplotype blocks harboring the SNPs that were found to be associated with PBTs. Haplotypes with a frequency \> 1% were considered in the blocks with different haplotype distribution between cases and controls (*p* \< 0.1). Although selection of SNPs for the analyses was based on a priori knowledge from candidate gene-association studies on adults, the possibility of false-positive findings was considered by providing the reference *p* value for an experiment-wide significance with Bonferroni correction (0.0002 for an experiment-wide significance level of 0.05, and 0.0004 for a significance level of 0.10). The analyses were carried out using PLINK v1.07 \[[@R50]\] and SAS statistical software version 9.3 (SAS Institute, Inc., Cary, NC, USA).

URLs {#s4_4}
----

PLINK: [http://pngu.mgh.harvard.edu/\~purcell/plink/](http://pngu.mgh.harvard.edu/~purcell/plink//)

SAS: [http://www.sas.com/](http://www.sas.com//)
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